Literature DB >> 21775825

ADHD in adults: current treatment trends with consideration of abuse potential of medications.

Alice R Mao1, Thomas Babcock, Matthew Brams.   

Abstract

OBJECTIVE: To review the literature describing impairments in educational, occupational, and social functioning in adults with attention-deficit/hyperactivity disorder (ADHD), current treatment trends, and factors that may influence the abuse potential of long-acting medications used to treat ADHD in adults.
METHODS: A MEDLINE search was conducted to identify articles relating to functional impairments and treatment options for adults with ADHD, as well as the abuse potential of ADHD medications.
RESULTS: ADHD is one of the most common psychiatric behavioral disorders in children, and its symptoms have been shown to persist into adulthood. Symptoms of ADHD may occur at home, school, work, or in social situations, and symptom occurrence in these different settings can have a profound negative impact for adults with ADHD. Impairments in educational, occupational, and social functioning in adults with ADHD have been described and are summarized in this review article. Although long-acting medications are more frequently prescribed for children with ADHD than short-acting medications, adults with ADHD are equally likely to be treated with short- and long-acting medications. While all medications used to treat ADHD in adults have potential for abuse, there are a number of factors that may contribute to a lower potential for abuse for long-acting agents compared with immediate-release medications.
CONCLUSION: Impairments from ADHD can be chronic and persistent and they can affect daily educational, occupational, and personal functioning. Adults, in particular, have responsibilities that can extend into the late evening hours so that clinicians need to consider medication duration of action when selecting a pharmacotherapy intervention for adults with ADHD.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21775825     DOI: 10.1097/01.pra.0000400261.45290.bd

Source DB:  PubMed          Journal:  J Psychiatr Pract        ISSN: 1527-4160            Impact factor:   1.325


  6 in total

1.  Cross-fostering differentially affects ADHD-related behaviors in spontaneously hypertensive rats.

Authors:  Angela C Gauthier; Nicole E DeAngeli; David J Bucci
Journal:  Dev Psychobiol       Date:  2015-02-02       Impact factor: 3.038

2.  Efficacy of atomoxetine versus midodrine for the treatment of orthostatic hypotension in autonomic failure.

Authors:  Claudia E Ramirez; Luis E Okamoto; Amy C Arnold; Alfredo Gamboa; André Diedrich; Leena Choi; Satish R Raj; David Robertson; Italo Biaggioni; Cyndya A Shibao
Journal:  Hypertension       Date:  2014-09-02       Impact factor: 10.190

3.  Extended-Release Mixed Amphetamine Salts vs Placebo for Comorbid Adult Attention-Deficit/Hyperactivity Disorder and Cocaine Use Disorder: A Randomized Clinical Trial.

Authors:  Frances R Levin; John J Mariani; Sheila Specker; Marc Mooney; Amy Mahony; Daniel J Brooks; David Babb; Yun Bai; Lynn E Eberly; Edward V Nunes; John Grabowski
Journal:  JAMA Psychiatry       Date:  2015-06       Impact factor: 21.596

4.  Physical exercise and catecholamine reuptake inhibitors affect orienting behavior and social interaction in a rat model of attention-deficit/hyperactivity disorder.

Authors:  Andrea M Robinson; Rachel L Eggleston; David J Bucci
Journal:  Behav Neurosci       Date:  2012-10-15       Impact factor: 1.912

Review 5.  Attention-deficit/hyperactivity disorder in postsecondary students.

Authors:  Kevin Nugent; Wallace Smart
Journal:  Neuropsychiatr Dis Treat       Date:  2014-09-26       Impact factor: 2.570

Review 6.  Long-acting stimulants for treatment of attention-deficit/hyperactivity disorder: a focus on extended-release formulations and the prodrug lisdexamfetamine dimesylate to address continuing clinical challenges.

Authors:  Frank A López; Jacques R Leroux
Journal:  Atten Defic Hyperact Disord       Date:  2013-04-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.